Immix Biopharma (NASDAQ:IMMX) Earns Outperform Rating from Analysts at Lifesci Capital

Investment analysts at Lifesci Capital initiated coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a report issued on Wednesday,Benzinga reports. The brokerage set an “outperform” rating and a $19.00 price target on the stock. Lifesci Capital’s price target points to a potential upside of 102.19% from the company’s previous close.

IMMX has been the topic of several other research reports. Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Morgan Stanley assumed coverage on Immix Biopharma in a research report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price target on the stock. Citizens Jmp restated a “market outperform” rating and issued a $23.00 price target on shares of Immix Biopharma in a research report on Friday, March 27th. Mizuho boosted their price target on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Finally, HC Wainwright boosted their price target on Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immix Biopharma has an average rating of “Moderate Buy” and a consensus target price of $19.40.

Immix Biopharma Stock Up 7.5%

IMMX stock traded up $0.66 during trading on Wednesday, hitting $9.40. The company had a trading volume of 1,260,868 shares, compared to its average volume of 972,400. The firm has a market cap of $511.29 million, a PE ratio of -10.21 and a beta of 0.10. Immix Biopharma has a 1-year low of $1.94 and a 1-year high of $11.61. The firm has a 50-day moving average price of $9.20 and a 200-day moving average price of $7.68.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Sell-side analysts anticipate that Immix Biopharma will post -0.7 earnings per share for the current year.

Institutional Investors Weigh In On Immix Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of IMMX. Vanguard Group Inc. grew its holdings in shares of Immix Biopharma by 4.5% in the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after acquiring an additional 31,625 shares during the period. Tocqueville Asset Management L.P. increased its holdings in shares of Immix Biopharma by 37.4% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after buying an additional 10,950 shares during the last quarter. Imprint Wealth LLC acquired a new stake in Immix Biopharma in the 3rd quarter valued at $141,000. Citadel Advisors LLC acquired a new stake in Immix Biopharma in the 3rd quarter valued at $188,000. Finally, Susquehanna International Group LLP grew its stake in shares of Immix Biopharma by 78.8% during the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock valued at $190,000 after acquiring an additional 40,032 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.